RNAC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RNAC is not a good buy right now for an impatient investor. The tape is still bearish (downtrend confirmed by moving averages and a worsening MACD), price is trading below key support, and pattern-based odds point to additional near-term weakness (next-week bias -6%). While Wall Street remains constructive on the longer-term story (Buy ratings with very high price targets), there is no fresh catalyst in the last week and Intellectia signals show no actionable buy setup today. I would hold off on buying until price reclaims broken support/turns the MACD and regains the pivot area (7.41).
Trend is bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating persistent downside momentum. MACD histogram is -0.0518 and negatively expanding, which typically signals the downtrend is strengthening rather than stabilizing. RSI_6 is ~29.94 (near oversold), suggesting selling pressure is heavy and a bounce is possible, but oversold alone is not a reliable ‘buy now’ trigger when trend/momentum are still deteriorating. Key levels: Pivot 7.405 is the upside line to reclaim for trend improvement; resistance at 7.764 (R1) then 7.986 (R2). Supports: S1 7.046 and S2 6.824; the stock at 6.77 is below S2, a bearish breakdown that often invites follow-through selling unless it quickly recovers above ~6.82–7.05.
Analyst-viewed ‘mispriced asset’ narrative: H.C. Wainwright reiterated Buy and argued RNAC’s valuation is disproportionate to potential, highlighting a registration-aligned Phase 3 path and a large myasthenia gravis population. BTIG reiterated Buy and raised its target after positive Phase 2 Descartes-08 data in SLE (strong response/remission figures), supporting platform credibility. Financial trend improvement in 2025/Q3 (loss narrowed materially YoY) can help sentiment at the margin.
with bearish MA stack and worsening MACD suggests downside continuation risk. The company remains loss-making (2025/Q3 net income -$35.9M; EPS -1.38), typical for development-stage biotech but a headwind without near-term catalysts. Extremely high implied volatility signals meaningful uncertainty and can coincide with sharp drawdowns. Pattern-based projection also leans negative over the next week (~-6.24%).
Latest quarter: 2025/Q3. Revenue rose to $452K (+16.80% YoY), but the business is still pre-commercial. Net income improved to -$35.902M (48.46% improvement YoY, i.e., a narrower loss), and EPS improved to -1.38 (+22.12% YoY). Gross margin is listed at 100% (flat YoY), which is not very informative at this revenue scale; the key takeaway is improving loss trend, but continued cash burn risk remains until major clinical/regulatory milestones.
Recent analyst trend is positive overall, with price targets remaining very high versus the current price despite one notable trim. On 2025-11-19, H.C. Wainwright lowered its target to $30 from $40 but kept a Buy, framing RNAC as deeply mispriced with a high-likelihood, registration-aligned Phase 3 path in MG. On 2025-11-14, BTIG raised its target to $44 from $42 and kept a Buy after strong Phase 2 SLE data (even though management planned to pause SLE and shift focus to myositis). Wall Street pros: large upside optionality tied to clinical/regulatory success and perceived valuation disconnect. Cons: execution risk, development prioritization shifts, and the stock’s current bearish trading action suggesting the market is not rewarding the story near-term.
